SCHEMBL5137683

SCHEMBL5137683

CCCCn1c(CN(Cc2ccccc2)Cc2ccc3c(c2)OCCO3)cnc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.53
PTGDR2 Q9Y5Y4 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 4/20 0.39
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GBA1 P04062 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C8 P10632 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912837 0.98 C5AR1 (0.55) C5AR1PTGDR2SMN1; SMN2TDP1TSHR
SCHEMBL5137517 0.97 C5AR1 (0.50) C5AR1PTGDR2SMN1; SMN2TDP1TSHR
SCHEMBL5134857 0.94 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5137292 0.94 C5AR1 (0.46) C5AR1PTGDR2SMN1; SMN2TDP1TSHR
SCHEMBL5134695 0.94 C5AR1 (0.47) C5AR1PTGDR2SMN1; SMN2TDP1TSHR
SCHEMBL647999 0.92 C5AR1 (0.62) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL650295 0.92 C5AR1 (0.48) C5AR1PTGDR2TSHRLMNACYP2C8
SCHEMBL1912862 0.92 C5AR1 (0.49) C5AR1PTGDR2SMN1; SMN2TDP1TSHR
SCHEMBL5135566 0.92 C5AR1 (0.57) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL648765 0.92 C5AR1 (0.47) C5AR1PTGDR2SMN1; SMN2TDP1CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed